https://www.taxtmi.com/notifications?id=137445 Exemption from central tax is granted for specified medicines used in COVID-19 treatment under the Uttarakhand Goods and Services Tax Act, 2017. Tocilizumab and Amphotericin B are exempted at nil rate, while Remdesivir, Heparin, Itolizumab, Posaconazole, Infliximab, Bamlanivimab & Etesevimab, Casirivimab & Imdevimab, 2-Deoxy-D-Glucose, and Favipiravir are taxable at 2.5%. The notification applies to Chapter 30 goods and operates from 1 October 2021 to 31 December 2021. en-us Fri, 10 Dec 2021 00:00:00 +0530 Sat, 20 Jun 2026 10:51:00 +0530 TaxTMI RSS Generator https://www.taxtmi.com/notifications?id=137445 Exemption from central tax is granted for specified medicines used in COVID-19 treatment under the Uttarakhand Goods and Services Tax Act, 2017. Tocilizumab and Amphotericin B are exempted at nil rate, while Remdesivir, Heparin, Itolizumab, Posaconazole, Infliximab, Bamlanivimab & Etesevimab, Casirivimab & Imdevimab, 2-Deoxy-D-Glucose, and Favipiravir are taxable at 2.5%. The notification applies to Chapter 30 goods and operates from 1 October 2021 to 31 December 2021. Notifications GST - States Fri, 10 Dec 2021 00:00:00 +0530 https://www.taxtmi.com/notifications?id=137445